In particular, it may be that the detrimental effect of the Met66 allele, described in animal models and in vitro (e.g., altered BDNF intracellular trafficking), is reversed and thus becomes beneficial in RR-MS patients. This evidence concerns the gene BDNF and myeloid sarcoma.